CYCLOFLUIDIC ANNOUNCE DRUG DISCOVERY AGREEMENT WITH TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE
Agreement combines TRI-I TDI’s integrated academic research network and world class scientific teams with Cyclofluidic’s proprietary chemistry platform to identify novel s...
Ubiquigent and Cyclofluidic enter into collaboration to build novel Ubiquitin system targeted libraries
Dundee, UK, 3rd June 2015: Ubiquigent Limited, a company specialising in ubiquitin cell-signalling system drug discovery capabilities and services, and Cyclofluidic Limited, a...
HitGen and Cyclofluidic Collaborate on Lead Development Programme
HitGen Ltd today announced that it has entered into research collaboration with Cyclofluidic Ltd, UK, using hits obtained from HitGen’s proprietary lead discovery technology...
MRCT and Cyclofluidic Announce Successful Collaboration
Cyclofluidic has been collaborating with MRCT to develop advanced tools against important cancer target hepsin. The collaboration used the Cyclofluidic CyclOps integrated synt...
Cyclofluidic and Sanofi publish results of sucessful technology evaluation
Scientists from Sanofi and Cyclofluidic published a paper in ACS Medicinal Chemistry Letters this month showing results of a technology evaluation study. The blinded study com...